246 related articles for article (PubMed ID: 38331983)
1. Dolutegravir based therapy showed CD4
Gebremedhin T; Aynalem M; Adem M; Geremew D; Aleka Y; Kiflie A
Sci Rep; 2024 Feb; 14(1):3297. PubMed ID: 38331983
[TBL] [Abstract][Full Text] [Related]
2. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
Hui X; Gan X; Li Q; Sun W
Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
[TBL] [Abstract][Full Text] [Related]
4. Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first-line antiretroviral therapy regimen in Zimbabwe.
Kouamou V; Washaya T; Mapangisana T; Ndhlovu CE; Manasa J
AIDS; 2024 Apr; 38(5):689-696. PubMed ID: 38227596
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Maggiolo F; Gulminetti R; Pagnucco L; Digaetano M; Cervo A; Valenti D; Callegaro A; Mussini C
BMC Infect Dis; 2022 Oct; 22(1):782. PubMed ID: 36224538
[TBL] [Abstract][Full Text] [Related]
7. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Dooley KE; Kaplan R; Mwelase N; Grinsztejn B; Ticona E; Lacerda M; Sued O; Belonosova E; Ait-Khaled M; Angelis K; Brown D; Singh R; Talarico CL; Tenorio AR; Keegan MR; Aboud M;
Clin Infect Dis; 2020 Feb; 70(4):549-556. PubMed ID: 30918967
[TBL] [Abstract][Full Text] [Related]
9. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
[TBL] [Abstract][Full Text] [Related]
10. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
De Miguel R; Rial-Crestelo D; Dominguez-Dominguez L; Montejano R; Esteban-Cantos A; Aranguren-Rivas P; Stella-Ascariz N; Bisbal O; Bermejo-Plaza L; Garcia-Alvarez M; Alejos B; Hernando A; Santacreu-Guerrero M; Cadiñanos J; Mayoral M; Castro JM; Moreno V; Martin-Carbonero L; Delgado R; Rubio R; Pulido F; Arribas JR;
EBioMedicine; 2020 May; 55():102779. PubMed ID: 32408111
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
[TBL] [Abstract][Full Text] [Related]
14. Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine.
Fernández-González M; García JA; Padilla S; García-Abellán J; Agulló V; Gutiérrez F; Masiá M
J Antimicrob Chemother; 2020 Mar; 75(3):668-674. PubMed ID: 31769846
[TBL] [Abstract][Full Text] [Related]
15. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya J; Dueñas C; Irazola I; de Los Santos I; de la Fuente S; Gil D; Hernández C; Galindo MJ; Gómez J; Delgado E; Moreno-García E; Pousada G; Aldámiz T; Iribarren JA; Guerra JM; Morán MÁ; Galera C; De La Fuente J; Peláez A; Cervero M; Garcinuño M; Montero M; Ceballos F; Buzón L;
Medicine (Baltimore); 2022 Jun; 101(24):e29252. PubMed ID: 35713430
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.
Zhao F; Rao M; Chen W; Cai K; Zhang L; Xu L; Sun L; Liu X; He Y; Wang H
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S16-S19. PubMed ID: 36094510
[TBL] [Abstract][Full Text] [Related]
18. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
19. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
Cahn P; Rolón MJ; Figueroa MI; Gun A; Patterson P; Sued O
J Int AIDS Soc; 2017 May; 20(1):21678. PubMed ID: 28537061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]